Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J Foster

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Neuron|September 13, 2016
Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine ReleaseDaniel J Foster, Jermaine M Wilson, Daniel H Remke, et al.
Molecular Psychiatry|August 18, 2018
Activation of the mGlu<sub>1</sub> metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M<sub>4</sub> muscarinic receptor allosteric modulatorsSamantha E Yohn, Daniel J Foster, Dan P Covey, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 1, 2017
Co-Activation of Metabotropic Glutamate Receptor 3 and Beta-Adrenergic Receptors Modulates Cyclic-AMP and Long-Term Potentiation, and Disrupts Memory ReconsolidationAdam G Walker, Douglas J Sheffler, Andrew S Lewis, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2015
Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 miceTristano Pancani, Daniel J Foster, Mark S Moehle, et al.
ACS Chemical Neuroscience|February 5, 2025
Further Optimization of the mGlu<sub>1</sub> PAM VU6024578/BI02982816: Discovery and Characterization of VU6033685Carson W Reed, Jacob F Kalbfleisch, Jeremy A Turkett, et al.
ACS Pharmacology & Translational Science|August 23, 2021
Discovery of the First Selective M<sub>4</sub> Muscarinic Acetylcholine Receptor Antagonists with <i>in Vivo</i> Antiparkinsonian and Antidystonic EfficacyMark S Moehle, Aaron M Bender, Jonathan W Dickerson, et al.
Journal of Medicinal Chemistry|April 13, 2022
Development of <b>VU6019650</b>: A Potent, Highly Selective, and Systemically Active Orthosteric Antagonist of the M<sub>5</sub> Muscarinic Acetylcholine Receptor for the Treatment of Opioid Use DisorderAaron T Garrison, Douglas L Orsi, Rory A Capstick, et al.
Neuron|May 5, 2015
Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR CurrentsJerri M Rook, Zixiu Xiang, Xiaohui Lv, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Neuron|September 13, 2016
Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine ReleaseDaniel J Foster, Jermaine M Wilson, Daniel H Remke, et al.
Molecular Psychiatry|August 18, 2018
Activation of the mGlu<sub>1</sub> metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M<sub>4</sub> muscarinic receptor allosteric modulatorsSamantha E Yohn, Daniel J Foster, Dan P Covey, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 1, 2017
Co-Activation of Metabotropic Glutamate Receptor 3 and Beta-Adrenergic Receptors Modulates Cyclic-AMP and Long-Term Potentiation, and Disrupts Memory ReconsolidationAdam G Walker, Douglas J Sheffler, Andrew S Lewis, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2015
Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 miceTristano Pancani, Daniel J Foster, Mark S Moehle, et al.
ACS Chemical Neuroscience|February 5, 2025
Further Optimization of the mGlu<sub>1</sub> PAM VU6024578/BI02982816: Discovery and Characterization of VU6033685Carson W Reed, Jacob F Kalbfleisch, Jeremy A Turkett, et al.
ACS Pharmacology & Translational Science|August 23, 2021
Discovery of the First Selective M<sub>4</sub> Muscarinic Acetylcholine Receptor Antagonists with <i>in Vivo</i> Antiparkinsonian and Antidystonic EfficacyMark S Moehle, Aaron M Bender, Jonathan W Dickerson, et al.
Journal of Medicinal Chemistry|April 13, 2022
Development of <b>VU6019650</b>: A Potent, Highly Selective, and Systemically Active Orthosteric Antagonist of the M<sub>5</sub> Muscarinic Acetylcholine Receptor for the Treatment of Opioid Use DisorderAaron T Garrison, Douglas L Orsi, Rory A Capstick, et al.
Neuron|May 5, 2015
Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR CurrentsJerri M Rook, Zixiu Xiang, Xiaohui Lv, et al.
Pageof 4